{"schema_version":"secwatch.filing_event.v1","accession":"0000313143-22-000032","form_type":"8-K","ticker":"HAE","cik":"0000313143","company_name":"HAEMONETICS CORP","filed_at":"2022-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.167063+00:00","generated_at":"2026-06-25T01:24:53.437521+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"EVP & General Counsel Michelle Basil to depart Haemonetics by Oct 31, 2022","bullets":["Michelle L. Basil, EVP and General Counsel, will transition from Haemonetics effective October 31, 2022.","She will remain in her role through the Retention Date to ensure a seamless transition while a successor is sought.","Under the Agreement, she will receive a $500,000 retention bonus if she stays through Oct 31 without resignation or cause termination.","Her base salary continues unchanged and outstanding equity awards vest through Retention Date; she will not receive FY2023 short-term incentive bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0000313143-22-000032","json":"https://secwatch.observer/filing/0000313143-22-000032.json","markdown":"https://secwatch.observer/filing/0000313143-22-000032.md","text":"https://secwatch.observer/filing/0000313143-22-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000032/0000313143-22-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000032/hae-20220611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:24:53.437521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"913e8bbc3f","claim":"Michelle L. Basil changed role as Executive Vice President, General Counsel at HAEMONETICS CORP.","evidence_excerpt":"On June 16, 2022, Haemonetics Corporation (the “Company”) announced that Michelle L. Basil, Executive Vice President, General Counsel has decided to transition from the Company effective October 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000032/0000313143-22-000032-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"transition"},{"label":"Role","value":"Executive Vice President, General Counsel"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}